(Q37352425)

19 August 2017

1 reference

title

High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy (English)

1 reference

19 August 2017

Yujian Zhang

1

1 reference

19 August 2017

Ira Pastan

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 December 2008

1 reference

19 August 2017

published in

Clinical Cancer Research

1 reference

19 August 2017

volume

14

1 reference

19 August 2017

issue

24

1 reference

19 August 2017

page(s)

7981-7986

1 reference

TACE: a new target in epidermal growth factor receptor dependent tumors

19 August 2017

cites work

1 reference

12 December 2020

Novel functions of TIMPs in cell signaling

1 reference

12 December 2020

Transmodulation of cell surface regulatory molecules via ectodomain shedding

1 reference

12 December 2020

Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody

1 reference

12 December 2020

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

1 reference

12 December 2020

ADAMs: key components in EGFR signalling and development

1 reference

12 December 2020

Soluble interleukin-2 receptor in cancer

1 reference

12 December 2020

Mesothelin-family proteins and diagnosis of mesothelioma

1 reference

12 December 2020

Shedding light on ADAM metalloproteinases

1 reference

12 December 2020

Isolation of interstitial fluid from rat mammary tumors by a centrifugation method

1 reference

12 December 2020

Monoclonal antibodies in cancer therapy: 25 years of progress

1 reference

12 December 2020

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

12 December 2020

Protein ectodomain shedding

1 reference

12 December 2020

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

1 reference

12 December 2020

Drug penetration in solid tumours

1 reference

12 December 2020

Transport of molecules, particles, and cells in solid tumors

1 reference

12 December 2020

Mesothelin targeted cancer immunotherapy

1 reference

12 December 2020

Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha

1 reference

12 December 2020

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 reference

12 December 2020

131I-tositumomab therapy as initial treatment for follicular lymphoma.

1 reference

12 December 2020

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients

1 reference

12 December 2020

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

1 reference

12 December 2020

A phase II study of the immunotoxin N901-blocked ricin in small-cell lung cancer

1 reference

12 December 2020

Tissue inhibitors of metalloproteinases: evolution, structure and function

1 reference

12 December 2020

Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice

1 reference

12 December 2020

Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance

1 reference

12 December 2020

Alemtuzumab in chronic lymphocytic leukemia

1 reference

12 December 2020

Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors

1 reference

12 December 2020

Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo.

1 reference

12 December 2020

MMP1 and MMP3 polymorphisms in promoter regions and cancer

1 reference

12 December 2020

Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption

1 reference

12 December 2020

Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab

1 reference

12 December 2020

Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier

1 reference

12 December 2020

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

12 December 2020

Immunotoxin treatment of cancer

1 reference

12 December 2020

Immunotoxin therapy of cancer

1 reference

12 December 2020

Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy

1 reference

12 December 2020

Strategies for optimizing combinations of molecularly targeted anticancer agents

1 reference

12 December 2020

Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation

1 reference

12 December 2020

Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Strategies for MMP inhibition in cancer: innovations for the post-trial era.

1 reference

12 December 2020

(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase

1 reference

12 December 2020

Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors

1 reference

12 December 2020

Stimulation of cleavage of membrane proteins by calmodulin inhibitors

1 reference

12 December 2020

Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases

1 reference

12 December 2020

Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme

1 reference

12 December 2020

ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters

1 reference

12 December 2020

Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer.

1 reference

12 December 2020

10.1158/1078-0432.CCR-08-0324

Identifiers

DOI

1 reference

release_22oajagldbbotetkvc43zf4224

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/22oajagldbbotetkvc43zf4224

24 November 2022

mapped directly with Wikidata item

PMC publication ID

7257036

0 references

1 reference